Association of Cystatin C with Metabolic Syndrome and Its Prognostic Performance in Non-ST-Segment Elevation Acute Coronary Syndrome with Preserved Renal Function

Table 6

Association between Cystatin C and cardiovascular outcomes.

		Unadjusted			Adjusted model 1			Adjusted model 2
Outcome variables	HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value
MACEs	2.876	(1.739–4.756)	<0.001	2.677	(1.566–4.576)	<0.001	2.609	(1.295–5.257)	0.007
Cardiac death	4.780	(1.362–16.778)	0.015	4.147	(1.097–15.672)	0.036	4.400	(0.845–22.896)	0.078
Non-fatal MI	2.036	(0.812–5.106)	0.129	2.373	(0.887–6.346)	0.085	4.041	(1.023–15.964)	0.046
TVR	2.649	(1.098–6.390)	0.030	2.351	(0.912–6.062)	0.077	1.563	(0.426–5.731)	0.500
Heart failure	4.955	(1.070–22.942)	0.041	3.000	(0.589–15.293)	0.186	2.958	(0.355–24.633)	0.316
Non-fatal stroke	1.677	(0.280–10.043)	0.571	1.750	(0.281–10.894)	0.548	1.787	(0.111–28.837)	0.682

High cystatin C is defined as cystatin C concentration > 0.90 mg/L.
Univariate and multivariate Cox proportional regression analyses are applied.
Model 1 is adjusted for age, gender, BMI, smoking, hypertension, diabetes, LDL-C, and HDL-C.
Model 2 is adjusted for model 1, eGFR-MDRD, CRP, Killip class > 1, GRACE score, SYNTAX score, ACEI/ARB, beta-blocker, and PCI/CABG.
Abbreviations. MACEs: major adverse cardiovascular events; MI: myocardial infarction; TVR: target vessel revascularization.